KMT2A and leukemia: Compound 1 exhibited strong antitumor activities with EC50s of 4.7-11 μM against proliferation of MLL-r leukemia cells Molm-13, MV4;11 and THP-1 (with MLL-AF9) (Figure 5A, Figure S6 and Table S1).